The intake of flavonoids, stilbenes, and tyrosols, mainly consumed through red wine and virgin olive oil, is associated with lower carotid and femoral subclinical atherosclerosis and coronary calcium

Henry Montero Salazar1 · Raquel de Deus Mendonça2 · Martín Laclaustra3,4,5 · Belén Moreno-Franco3,4 · Agnete Åkesson6 · Pilar Guallar-Castillón1,7,8 · Carolina Donat-Vargas1,6,7,8

Received: 5 October 2021 / Accepted: 1 February 2022 / Published online: 7 March 2022 © The Author(s) 2022

Abstract

Purpose It is suggested that polyphenols back the cardiovascular protection offered by the Mediterranean diet. This study evaluates the association of specific types of dietary polyphenols with prevalent subclinical atherosclerosis in middle-aged subjects.

Methods Ultrasonography and TC were performed on 2318 men from the Aragon Workers Health Study, recruited between 2011 and 2014, to assess the presence of plaques in carotid and femoral arteries and coronary calcium. Polyphenol intake was assessed using a validated semi-quantitative 136-item food frequency questionnaire. The Phenol Explorer database was used to derive polyphenol class intake. Logistic and linear regressions were used to estimate the cross-sectional association of polyphenols intake with femoral and carotid subclinical atherosclerosis and coronary calcium.

Results A higher intake of flavonoids (third vs. first tertile) was associated with a lower risk of both carotid (OR 0.80: CI 95% 0.62–1.02; \( P \) trend 0.094) and femoral (0.62: 0.48–0.80, \( P \) trend < 0.001) subclinical atherosclerosis. A higher intake of stilbenes was associated with a lower risk of femoral subclinical atherosclerosis (0.62: 0.46–0.83; \( P \) trend 0.009) and positive coronary calcium (0.75: 0.55–1.03; \( P \) trend 0.131). A higher intake of tyrosols was also associated with a lower risk of positive coronary calcium (0.80: 0.62–1.03; \( P \) trend 0.111). The associations remained similar when adjusted for blood lipids and blood pressure.

Conclusion Dietary flavonoids, stilbenes, and tyrosols, whose main sources are red wine and virgin olive oil, are associated with lower prevalence of subclinical atherosclerosis in middle-aged subjects.

Keywords Stilbenes · Flavonoids · Red wine · Subclinical coronary atherosclerosis · Coronary calcium · Cross-sectional cohort study

Abbreviations

AWHS Aragon Workers´ Health Study
CVD Cardiovascular disease

CI Confidence intervals
CACS Coronary Artery Calcium Score
FFQ Food Frequency Questionnaire

1 Department of Preventive Medicine and Public Health and Microbiology, Universidad Autónoma de Madrid, CEI UAM+CSIC+ IdiPaz, Madrid, Spain
2 Department of Clinical and Social Nutrition. School of Nutrition, Universidade Federal de Ouro Preto, Ouro Preto, Brasil
3 Instituto de Investigación Sanitaria (IIS) Aragón, Hospital Universitario Miguel Servet, Zaragoza, Spain
4 CIBERCV (CIBER of Cardiovascular) Instituto de Salud Carlos III, Madrid, Spain
5 Department of Medicine, University of Zaragoza, Zaragoza, Spain
6 Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine (IMM), Karolinska Institutet, Stockholm, Sweden
7 CIBERESP (CIBER of Epidemiology and Public Health), Instituto de Salud Carlos III, Madrid, Spain
8 IMDEA-Food Institute, Madrid, Spain
Background

Polyphenolic compounds are secondary plant metabolites found in a variety of plant-derived foods, including fruits, nuts, tea, cocoa products, coffee, vegetables, olive oil, soy products, as well as red wine [1]. Polyphenols comprise flavonoids (such as flavan-3-ols, flavonols, anthocyanins, flavanones, flavones, and isoflavones) and phenolic acids, stilbenes, lignans, and other minor polyphenols. These compounds are intensively studied for their potential health benefits in chronic diseases, such as cardiovascular diseases (CVD). High dietary polyphenol intake, especially flavonoids, has consistently been associated with a reduced incidence of cardiovascular events [2–5].

Protective effects of polyphenols against inflammatory and oxidative processes, and endothelial dysfunction, which are implicated in the atherosclerosis development, have also been evidenced [6–9]. In a sub-study of 1139 high-risk participants, which was carried out within the PREDIMED trial, a higher polyphenol exposure measured as urinary polyphenol excretion was associated with lower levels of inflammatory biomarkers, suggesting a dose-dependent anti-inflammatory effect of polyphenols. High polyphenol intake also improved blood pressure and the lipid profile [9].

Atherosclerosis, which underlies CVD, is a complex process in which fat, inflammation cells, scar tissue, and deposits of calcium accumulate within the walls of the arteries [10]. The presence of calcium in the coronary arteries is an indicator of subclinical atherosclerotic disease and a marker of coronary damage [11], as well as, a strong and independent predictor of future coronary heart disease [12, 13]. Also, the presence of atherosclerotic plaques in peripheral arteries is considered a valuable evaluation of subclinical atherosclerosis [14]. Association of atherosclerosis with risk factors may be stronger in femoral arteries than carotid or coronary arteries, at least in the middle-aged adult [14].

To date, however, no epidemiological study has yet evaluated the direct association of dietary polyphenol intake with subclinical atherosclerosis, a missing step from their influence in risk factors and pathogenic mechanisms toward clinical disease. The aim of this study is to examine the association of specific types of dietary polyphenols with plaques in the carotid and femoral arteries and coronary calcium in middle-aged asymptomatic subjects with a low prevalence of clinical comorbidities.

Methods

Study design and population

The Aragon Workers’ Health Study (AWHS) is a prospective cohort whose design and methodology has been described in detail elsewhere [14, 15]. Study participants are middle-aged workers, of the Opel Spain automobile assembly plant recruited during an annual physical examination in 2009–2010 (participation rate 95.6%). Between January 2011 and December 2014, all participants aged 39–59 (34% of the initial sample) and free of CVD at baseline were invited to undergo noninvasive subclinical atherosclerosis imaging as well as questionnaires on cardiovascular and lifestyle factors. The data used for this study were cross-sectional.

The study was approved by the Clinical Research Ethics Committee of Aragon (CEIC). All participants provided written informed consent.

Dietary polyphenol intake

Dietary polyphenol intake was assessed at baseline using a 136-item FFQ previously validated and repeatedly re-evaluated in Spain [16–18]. The FFQ grouped the foods into the following categories: fruits (fresh, dried, jam, in the yogurt), vegetables, legumes, oils (olive, virgin olive, sunflower and corn), grains (rice and pasta), breads (white and whole), artisanal (homemade) and industrialized pastries, juices (natural, packaged), breakfast cereals, chocolate and cocoa products, coffee and tea beverages, and alcoholic drinks (wine, beer, spirits). The frequency of food consumption was collected by nine categories (ranging from never or almost never to more than six servings per day). A standard portion size for each food item was also included.

For the evaluation of the polyphenols intake, foods with only traces or without polyphenols (dairy, eggs, meat, fish, butter, margarine, lard, carbonated drinks, water, soups and creams, mayonnaise, salt, sugar, saccharin) were excluded [19].

Data on the polyphenol content in foods were obtained from the Phenol Explorer database (www.phenolexplorer.eu). For three specific foods not identified in Phenol Explorer (leek, thistle, and honey) we used the United States Department of Agriculture (USDA) database (https://www.ars.usda.gov/nutrientdata). Polyphenol content was analyzed by chromatography after hydrolysis and expressed as aglycones.
Polyphenol content from recipes and processed foods was calculated based on their separated ingredients. For raw foods, the Retention Factor (RF) was applied as a way to compensate for losses or gains in nutrients during food processing. A RF, considering the domestic cooking practices (i.e., boiling, steaming, frying, microwaving) and processing, was applied for cooked and processed foods [19]. For this purpose, RF was considered when the polyphenol content was only available in the Phenol Explorer in the raw form of the food.

Individual polyphenol intake from each food was calculated by multiplying the individual polyphenol content by the daily consumption of each food. The total dietary polyphenols were adjusted for total energy intake using the residual method [21].

### Subclinical atherosclerosis imaging

The presence of plaques in carotid and femoral arteries was determined using an ultrasound system IU22 Philips (Philips Healthcare, Bothell, Washington). Ultrasound images were acquired with linear high-frequency 2-dimensional probes (Philips Transducer L9-3, Philips Healthcare), using the Bioimage Study protocol for the carotid arteries [22] and a protocol that was specifically designed for the femoral arteries [23]. Inspection sweeps were obtained on the right and left side of the carotid (common, internal, external, and bulb) and femoral territories. The presence of a plaque was defined as a focal structure protruding ≥ 0.5 mm into the lumen artery or reaching a thickness ≥ 50% of the surrounding intima. All measurements were analyzed using electrocardiogram (ECG)-gated frames and obtained at the end of the diastole (R-wave) [24].

Coronary calcium was obtained with a multi-detector-row CT scanner (Mx 8000 IDT 16, Philips Medical Systems, Best, the Netherlands) using a low-dose, prospectively ECG-triggered, and a high-pitch spiral acquisition protocol. Coronary calcium was quantified with calcium scoring software (Workspace CT viewer, Philips Medical Systems) that follows the Agatston method [25]. Agatston’s method is a summed score obtained from all coronary calcified lesions, accounting for both, the total area as well as the maximum density of coronary calcium. A high coronary artery calcium score (CACS) is a strong indicator of extensive disease with a significant amount of calcium deposits. CACS is the reference standard and the most commonly used coronary artery calcium score in clinical practice [25]. Having a CACS > 0 represents the presence of calcium and has been associated with increases in coronary heart disease rates [26].

Imaging of subclinical atherosclerosis was performed at the AWHS Clinic located at the Hospital Universitario Miguel Servet in Zaragoza, Spain [14, 15].

### Additional data collection

Information on demographic characteristics was self-reported and included age, sex, marital status (married, not married), and educational level (middle school, high school, professional training, and college). Study participants undergo a standardized physical exam, including weight (kg), height (cm), waist circumference, blood pressure (BP), medical history, and the current use of medication. Hypertension was defined if use of antihypertensive medication was self-reported, or the reported systolic blood pressure was ≥ 131 mmHg or the diastolic ≥ 81 mmHg. Body mass index (BMI) (kg/m²) was calculated by dividing weight by height squared.

Each participant also provided a sample of blood and urine after overnight fasting (> 8 h) for laboratory analyses and for biobanking. Total cholesterol, high-density lipoprotein cholesterol (HDL-c), triglycerides, and fasting serum glucose concentrations were determined by enzyme analysis using the ILAB 650 analyzer from Instrumentation Laboratory (Bedford, MA, USA). Low-density lipoprotein cholesterol (LDL-c) was calculated using the Friedewald formula when the triglyceride levels were < 400 mg/dl [27]. Hypercholesterolemia was considered when use of lipid-lowering medication was reported or having total cholesterol ≥ 200 mg/dL.

Lifestyle factors including physical activity smoking, and sleep duration (both on weekdays and weekends) were obtained by questionnaires. The leisure-time physical activities and time spent in sedentary activities (including sleep duration) were assessed using a formerly validated questionnaire, i.e., the Health Professionals’ Follow-up physical activity questionnaire [28]. Participants were asked about the time devoted to 17 different activities during the preceding year, and leisure-time physical activity was expressed in metabolic equivalents (METs)-h/week. Smoking habits were categorized as current smoking if the participant reported having smoked in the last year, former smoking if the participant had smoked at least 50 cigarettes in his lifetime, but not in the last year, and never smoking.

Physicians and nurses collecting these data underwent specific training and standardization programs organized by the study investigators. Compliance with study procedures was routinely monitored and deviations were
corrected. The study conforms to the ISO9001-2008 quality standard. All study procedures are described elsewhere [15].

**Statistical analysis**

Participants were categorized into tertiles of daily mg of total polyphenols intake, as well as into tertiles of each individual polyphenol intake, after adjusting for total energy intake using the residual method [21]. Spearman correlations were calculated between intakes of the different polyphenols. The contribution of the main food groups to polyphenol intake was also estimated.

We performed a standard binary logistic regression to estimate the odds ratio (OR) and corresponding 95% confidence intervals (CI) for the presence of at least one plaque in the carotid and femoral arteries as well as for having a positive coronary calcium score (CACS > 0 vs. CACS = 0) associated to total and per class dietary polyphenol intake. By linear regression, we also evaluated the mean difference of the CACS as log-transformed continuous score (log(CACS + 1)) according to tertiles of energy-adjusted dietary polyphenols intake. To calculate the P for trend, means of the polyphenol intakes in each tertile were used and treated as a continuous variable in the model. The ORs for the presence of plaques and positive CACS were also calculated using the polyphenols intake (mg/day) as a continuous variable.

We built three models with progressive adjustment for covariates that can operate as confounders [29]. Model 1 was adjusted for age (continuous, years) and total energy intake (Kcal/d); model 2 was further adjusted for marital status (married, not married), education (middle school, high school, professional training, and college), smoking (never, former, and current smoker), physical activity (in MET-h/wk.), BMI (<25, 25 to <30, ≥30 kg/m²), time spent sleeping during the weekdays (number of hours of sleep, continuous), time spent sleeping during the weekend (number of hours of sleep, continuous), alcohol consumption (g/d), total dietary fiber (g/day), and use of diabetes medication (yes, no); model 2 was considered the main model to assess the associations of polyphenol intake with subclinical atherosclerosis; and additionally, a model 3 was further adjusted for cardio-metabolic risk factors, which can potentially act as mediators, i.e., LDL cholesterol in blood (mg/dL), HDL cholesterol in blood (mg/dL), and systolic and diastolic blood pressure (mmHg). Because flavonoids and stilbenes were the polyphenols more correlated, we presented and compared the results obtained with the effects resulting from the analyses of the data with complete information for all variables. The complete case sensitivity analyses led to very similar results (data not shown).

We also performed interaction analysis between polyphenols and age, BMI, and smoking. P for interaction was obtained using the likelihood ratio test of the models with and without the interaction term. Finally, sensitivity analyses were performed after excluding those with prevalent diabetes (4.2%).

Participants’ characteristics were compared across the three categories of total polyphenol intake, using counts and percentages for categorical variables and means and standard deviations for continuous variables. P value estimates were based on one-way ANOVA for continuous variables and Pearson χ² test for categorical variables. For variables with imputed values, we used the P values from ordered logistic regression models.

The software used for statistical analysis was STATA/SE version 16.0 (Stata Corporation, Inc., Collage Station, TX, USA). All tests were two sided with the level of significance set at 0.05.

**Results**

Among the 2586 workers recruited into the AWHS imaging study, we excluded a minority of women (n = 132), and those with an extreme total energy intake (<600 or >4200 kcal) (n = 136), resulting in 2318 participants. Among them, plaques measurements in carotid and femoral were only available in 2183 and 2187 participants, respectively, and CACS measurements were only available for 1876 (Supplemental Fig. 1).

Total polyphenol intake ranged from 562 (±173) in the lowest tertile to 1314 (±326) mg/d in the highest. The class of polyphenols consumed the most (50% of the total intake) was flavonoids (546 ± 264 mg/d), and those consumed the least were stilbenes (4.5 ± 6.1 mg/d) and lignans (3.0 ± 1.3 mg/d), both together representing less than 1% of the total polyphenol intake (Table 1).

All participants were Caucasian males with a mean age of 51 ± 4 years. Among them, 4% were diabetic, 66% were hypertensive, 76% had hypercholesterolemia, and 24% were obese. Compared to those in the lowest tertile of total polyphenol intake, those in the highest were on average 1-year older, had more education, were more frequently current smokers, performed more physical activity, had a higher
Table 1 Characteristics of the study participants according to quartiles of energy-adjusted total polyphenols intake, the AWHS study (N=2318)

| Characteristic | Energy-adjusted total polyphenols intake (mg/d)* | Tertile 1 | Tertile 2 | Tertile 3 | P value |
|---------------|---------------------------------------------|---------|---------|---------|---------|
| n             |                                             | 773     | 773     | 772     | <0.001  |
| Total polyphenols (mg/d) |                                       | 754 (197) | 1055 (186) | 1501 (332) | <0.001  |
| Flavonoids (mg/d)   |                                       | 357 (137) | 512 (162) | 769 (279) | <0.001  |
| Phenolic acids (mg/d) |                                        | 349 (130) | 478 (137) | 630 (191) | <0.001  |
| Stilbenes (mg/d)    |                                        | 1.9 (3.09) | 4.09 (4.97) | 7.43 (7.79) | <0.001  |
| Lignans (mg/d)      |                                        | 2.55 (1.12) | 2.35 (1.14) | 2.5 (1.27) | <0.001  |
| Tyrosols (mg/d)     |                                        | 30.8 (26.6) | 42.7 (32.4) | 72.6 (61.9) | <0.001  |
| Alkylphenols (mg/d) |                                        | 7.8 (17.1) | 10.5 (19.4) | 12 (23.4) | <0.001  |
| Total energy intake (kcal) |                          | 2865 (610) | 2735 (606) | 2837 (609) | <0.001  |
| Age (years)         |                                        | 50.4 (4) | 50.8 (3.9) | 51.4 (3.7) | <0.001  |
| Married (%)         |                                        | 81      | 86.7    | 85.1    | 0.007   |
| Education (%)       |                                        | 54.6    | 46.6    | 48.7    | 0.019   |
| Middle school       |                                        | 46.6    | 13.1    | 9.18    |         |
| High school         |                                        | 54.6    | 33.5    | 35.2    | <0.001  |
| Professional training |                                    | 3.76    | 6.77    | 6.92    |         |
| Smoking (%)         |                                        | 23.2    | 24.5    | 23.1    |         |
| Never               |                                        | 54.6    | 56.4    | 58.2    |         |
| Former              |                                        | 40.5    | 44.7    | 49.5    |         |
| Current             |                                        | 20.1    | 16.8    | 19.8    |         |
| Physical activity (MET-h/week) |                  | 30.3 (21.3) | 31.2 (22.5) | 34.4 (24.1) | <0.001  |
| Body mass index (%) |                                        | 0.139   |         |         |         |
| <25 kg/m²           |                                        | 20.1    | 16.8    | 19.8    |         |
| 25 to <30 kg/m²     |                                        | 56.9    | 56.4    | 58.2    |         |
| ≥30 kg/m²           |                                        | 23.0    | 26.8    | 22.0    |         |
| Sleep duration (hours) |                                    | 6.31 (.95) | 6.37 (.93) | 6.26 (.98) | 0.0887  |
| During the weekdays |                                        | 7.28 (1.19) | 7.38 (1.1) | 7.25 (1.19) | 0.0894  |
| Alcohol consumption (g/d) |                            | 16.2 (17.1) | 19.3 (17.8) | 26.3 (21.7) | <0.001  |
| Total fiber intake (g/d) |                                | 22.8 (6.4) | 24.5 (7.4) | 27.3 (8.1) | <0.001  |
| LDL cholesterol in blood (mg/dL) |        | 136 (35) | 137 (31) | 138 (33) | 0.4237  |
| HDL cholesterol in blood (mg/dL) |                  | 51.8 (11.3) | 53.1 (11.3) | 54.1 (11.5) | <0.001  |
| Blood pressure (mmHg) |                                        | 125 (14) | 126 (14) | 125 (14) |         |
| Systolic            |                                        | 82.8 (9.7) | 83.1 (9.5) | 82.4 (9.2) | 0.3342  |
| Diastolic           |                                        | 6.31 (.95) | 6.37 (9.3) | 6.26 (9.8) | 0.3785  |
| Diabetes medication use (%) |            | 4.51     | 3.89    | 4.16    | 0.738   |
| Hypertension        |                                        | 64.8    | 68.6    | 65.7    | 0.263   |
| Hypercholesterolemia |                                    | 74.9    | 77      | 77.6    | 0.427   |
| Obesity             |                                        | 23      | 26.8    | 22      | 0.069   |
| Main food groups intake (g/day) |          | 239 (153) | 298 (165) | 364 (183) | <0.001  |
| Fruit               |                                        | 272 (110) | 318 (127) | 364 (136) | <0.001  |
| Vegetables          |                                        | 33.3 (12.1) | 32.7 (11.7) | 33.9 (14.1) | 0.187   |
| Legumes             |                                        | 18.6 (20.6) | 20.1 (20.2) | 21.6 (20.6) | 0.013   |
| Virgin olive oil    |                                        | 86.0 (57) | 121 (65) | 149 (81) | <0.001  |
| Coffee              |                                        | 2.44 (3.98) | 3.54 (5.65) | 5.57 (8.37) | <0.001  |
| Nuts                |                                        | 2.09 (4.21) | 3.55 (5.59) | 7.02 (10.38) | <0.001  |
| Chocolate           |                                        | 33.5 (58.9) | 76 (95.7) | 139.8 (150.2) | <0.001  |
| Red wine            |                                        | 239 (153) | 298 (165) | 364 (183) | <0.001  |

Continuous variables are presented as mean±standard deviation and categorical variables as percentage. P value estimates are based on one-way ANOVA for variables expressed as mean (standard deviation) or Pearson’s χ² test for variables expressed as percentages. For variables with imputed values, we used the P values from ordered logistic regression models.

*Energy-adjusted by the residual method
consumption of alcohol, and dietary fiber, as well as higher levels of HDL cholesterol (Table 1). Furthermore, those with the highest total polyphenol intake consumed more fruit, vegetables, virgin olive oil, coffee, nuts, chocolate, and red wine (Table 1).

The contributions of different foods to the total and types of polyphenol intake are shown in Table 2. Coffee, followed by red wine were the major contributors to the total polyphenol intake. Apples and pears, red wine, cherries/plums, and chocolate were the major contributors to flavonoids; coffee to phenolic acids; red wine to stilbenes; white bread to lignans; virgin olive oil to tyrosols; and whole bread coffee to alkylphenols.

Spearman’s correlations between the different polyphenol groups were mild to moderate; the higher correlation occurred between flavonoids and stilbenes ($\rho = 0.54$) (Supplemental Table 1).

Subclinical atherosclerosis was found in 72% of participants. Atherosclerosis was most common as femoral plaques (57%), followed by coronary calcification (40%) and carotid plaques (38%). A tendency to a lower risk of plaques in the carotid arteries ($-20\%$) was only observed in those subjects with a highest intake of flavonoids when compared to those with lowest consumption (Model 2, OR 0.80; CI 95% 0.62–1.02; $P$ trend 0.094) (Table 3). This association was maintained after adjusting for blood lipids and blood pressure (Model 3) and was minimally diluted when adjusting for stilbenes (Model 4). A similar lower risk of plaques in the femoral arteries ($-38\%$) was observed in those subjects with a higher intake of flavonoids (Model 2 OR 0.62; 0.48–0.80, $P$ trend < 0.001) but also in those with higher stilbenes intake (Model 2 OR 0.62; 0.46–0.83; $P$ trend 0.009) compared to those with lower consumption (Table 4). Likewise, the risk of plaques in the femoral arteries was reduced by a 4% (OR 0.94; CI 95% 0.90–0.98) for each 100 mg/day intake of flavonoids; and a 3% (OR 0.97; CI 95% 0.95–0.99) decreased risk of plaques in the femoral arteries for each 1 mg/day intake of stilbenes (not shown in tables).

The participants CACS mean was 122 ± 282. In this sample, those participants with the highest intake of stilbenes reduced their risk of having a positive CACS by 25% (OR 0.75; CI 95% 0.55–1.03), and those with the highest intake of tyrosols the reduction was 20% (OR 0.80; CI 95% 0.62–1.03) (Table 5). Also, when assessing the CACS as continuous, those with higher intake of stilbenes divided their CACS by 1.46, on average, with respect to those with the lowest tertile of intake (Model 2 difference of log-transformed CACS -0.41: −0.69 to −0.14; $P$ trend 0.019) (Supplemental Table 2).

Similar results were obtained when models were adjusted for non-wine alcohol consumption. There was no evidence of interaction by age, BMI, or smoking. Also, after excluding participants with diabetes, the results and main conclusions remained (data not shown).

### Discussion

This is the first epidemiological evidence on the association between dietary polyphenol intake and subclinical atherosclerosis. In this sample of middle-aged male workers,
among all types of polyphenols estimated from diet, flavo-
noids, stilbenes and tyrosols were those polyphenols more
consistently associated with a lower prevalence of subcli-
cal atherosclerosis. Dietary flavonoids (mainly from apples/
pears, red wine, cherries/ plums, and chocolate) were asso-
ciated with lower prevalence of plaques in the carotid and
femoral arteries, while stilbenes (largely from red wine) were
associated with a lower prevalence of plaques in the femoral
arteries and lower coronary calcium. Tyrosols also suggested
having a protective effect against coronary calcium. These
associations persisted after adjusting for blood lipids and
blood pressure, known mediators of atherosclerosis.

Table 3 Odds ratio (OR) and 95% confidence intervals (CI)
for the risk of the presence of at least one plaque in the carotid
arteries according to tertiles of energy-adjusted dietary polyphenols intake (n = 2183)

| Tertiles of energy-adjusted dietary polyphenols intake (mg/d) | Tertile 1 | Tertile 2 | Tertile 3 | P trend |
|-------------------------------------------------------------|----------|----------|----------|---------|
| Total polyphenols                                           |          |          |          |         |
| Prevalent cases/n   | 268/721  | 270/732  | 296/730  | 0.793   |
| Model 1. OR (95%CI) | Ref.     | 0.93 (0.75, 1.15) | 1.02 (0.82, 1.27) | 0.875   |
| Model 2. OR (95%CI) | Ref.     | 0.95 (0.76, 1.19) | 1.02 (0.80, 1.29) | 0.776   |
| Model 3. OR (95%CI) | Ref.     | 0.95 (0.75, 1.20) | 1.03 (0.81, 1.32) |         |
| Flavonoids         |          |          |          |         |
| Prevalent cases/n   | 291/724  | 267/730  | 276/729  | 0.064   |
| Model 1. OR (95%CI) | Ref.     | 0.77 (0.62, 0.96) | 0.80 (0.64, 0.99) |         |
| Model 2. OR (95%CI) | Ref.     | 0.79 (0.63, 1.00) | 0.80 (0.62, 1.02) | 0.126   |
| Model 3. OR (95%CI) | Ref.     | 0.77 (0.61, 0.97) | 0.81 (0.63, 1.03) |         |
| Model 4 OR (95%CI)  | Ref.     | 0.78 (0.61, 0.99) | 0.84 (0.64, 1.10) | 0.263   |
| Phenolic acids     |          |          |          |         |
| Prevalent cases/n   | 253/725  | 280/730  | 301/728  | 0.074   |
| Model 1. OR (95%CI) | Ref.     | 1.14 (0.91, 1.42) | 1.22 (0.98, 1.52) |         |
| Model 2. OR (95%CI) | Ref.     | 1.14 (0.91, 1.42) | 1.18 (0.94, 1.48) | 0.153   |
| Model 3. OR (95%CI) | Ref.     | 1.15 (0.91, 1.44) | 1.20 (0.95, 1.50) | 0.130   |
| Stilbenes          |          |          |          |         |
| Prevalent cases/n   | 265/729  | 264/723  | 305/731  | 0.311   |
| Model 1. OR (95%CI) | Ref.     | 0.93 (0.74, 1.18) | 1.07 (0.86, 1.34) |         |
| Model 2. OR (95%CI) | Ref.     | 0.92 (0.72, 1.17) | 0.89 (0.67, 1.18) | 0.536   |
| Model 3. OR (95%CI) | Ref.     | 0.94 (0.73, 1.20) | 0.93 (0.70, 1.25) | 0.758   |
| Model 4 OR (95%CI)  | Ref.     | 0.94 (0.74, 1.21) | 0.96 (0.71, 1.29) | 0.889   |
| Lignans            |          |          |          |         |
| Prevalent cases/n   | 264/730  | 294/725  | 276/728  | 0.741   |
| Model 1. OR (95%CI) | Ref.     | 1.17 (0.94, 1.45) | 1.05 (0.84, 1.30) |         |
| Model 2. OR (95%CI) | Ref.     | 1.18 (0.95, 1.48) | 1.07 (0.85, 1.34) | 0.609   |
| Model 3. OR (95%CI) | Ref.     | 1.18 (0.94, 1.47) | 1.07 (0.85, 1.35) | 0.600   |
| Tyrosols           |          |          |          |         |
| Prevalent cases/n   | 273/730  | 260/723  | 301/730  | 0.747   |
| Model 1. OR (95%CI) | Ref.     | 0.87 (0.70, 1.09) | 1.02 (0.82, 1.27) |         |
| Model 2. OR (95%CI) | Ref.     | 0.86 (0.69, 1.09) | 1.00 (0.80, 1.26) | 0.590   |
| Model 3. OR (95%CI) | Ref.     | 0.88 (0.70, 1.11) | 1.03 (0.82, 1.30) |         |
| Alkylphenols       |          |          |          |         |
| Prevalent cases/n   | 394/720  | 289/738  | 251/725  | 0.849   |
| Model 1. OR (95%CI) | Ref.     | 0.98 (0.78, 1.23) | 0.85 (0.68, 1.07) |         |
| Model 2. OR (95%CI) | Ref.     | 1.05 (0.83, 1.32) | 0.97 (0.76, 1.23) |         |
| Model 3. OR (95%CI) | Ref.     | 1.06 (0.83, 1.33) | 1.00 (0.79, 1.28) |         |

Model 1: Logistic regression model adjusted for age and total energy intake. Model 2: As in Model 1 and additionally adjusted for marital status, education, smoking, physical activity, sleep duration during week-
days and during the weekend, alcohol consumption, total fiber intake, body mass index, and diabetes medi-
cation use. Model 3: As in Model 2 and additionally adjusted for LDL and HDL cholesterol and systolic
and diastolic blood pressure. Model 4: As in Model 3 and flavonoids and stilbenes were mutually adjusted
CI confidence interval, OR odds ratio
A meta-analysis of 14 prospective cohort studies have shown that consumption of flavonoid-rich diets significantly decreased the risk of CVD [32]. A prior prospective cohort study of middle-aged Spanish adults found that, among different type of polyphenols, only dietary flavonoids were associated with a lower incidence of cardiovascular events [2]. In other Spanish cohort study of older adults at high cardiovascular risk, higher intakes of total polyphenols, lignans, flavonoids and hydroxybenzoic acids were associated with a lower risk of CVD [5] and subjects with high polyphenol intake, especially stilbenes and lignans, exhibited a reduced risk of overall mortality.
compared to lower intakes, but no significant associations for flavonoids or phenolic acids with all-cause mortality were found [5]. In this study, only flavonoids and stilbenes, whose main common source is red wine, were associated with lower prevalence of subclinical atherosclerosis.

Beyond the cardiovascular risk reduction already evidenced [33], light to moderate intake of red wine produces several beneficial effects on the vascular wall and blood cells and targeting all phases of the atherosclerotic process, from atherogenesis (functional disorder as flow-mediated

| Table 5 | Odds ratio (OR) and 95% confidence intervals (CI) for the risk of a positive coronary calcium Agatston Score (CACS > 0) according to tertiles of energy-adjusted dietary polyphenols intake (n = 1876) |
|---------|-------------------------------------------------------------|
| Total polyphenols | Tertiles of energy-adjusted dietary polyphenols intake (mg/d) | Tertile 1 | Tertile 2 | Tertile 3 | P trend |
| Prevalent cases/n | 239/611 | 254/638 | 254/627 |
| Model 1. OR (95%CI) | Ref. | 0.97 (0.76, 1.22) | 0.91 (0.72, 1.15) | 0.415 |
| Model 2. OR (95%CI) | Ref. | 0.92 (0.72, 1.18) | 0.84 (0.64, 1.09) | 0.183 |
| Model 3. OR (95%CI) | Ref. | 0.92 (0.72, 1.18) | 0.84 (0.64, 1.10) | 0.206 |
| Flavonoids | Prevalent cases/n | 244/622 | 251/627 | 252/627 |
| Model 1. OR (95%CI) | Ref. | 0.93 (0.73, 1.18) | 0.91 (0.72, 1.15) | 0.441 |
| Model 2. OR (95%CI) | Ref. | 0.94 (0.73, 1.21) | 0.88 (0.67, 1.15) | 0.346 |
| Model 3. OR (95%CI) | Ref. | 0.93 (0.72, 1.19) | 0.90 (0.68, 1.17) | 0.438 |
| Model 4. OR (95%CI) | Ref. | 0.95 (0.74, 1.23) | 0.96 (0.72, 1.28) | 0.807 |
| Phenolic acids | Prevalent cases/n | 239/626 | 243/614 | 265/636 |
| Model 1. OR (95%CI) | Ref. | 1.02 (0.80, 1.29) | 1.05 (0.84, 1.33) | 0.652 |
| Model 2. OR (95%CI) | Ref. | 0.98 (0.77, 1.24) | 0.99 (0.78, 1.26) | 0.950 |
| Model 3. OR (95%CI) | Ref. | 0.97 (0.76, 1.24) | 0.99 (0.78, 1.27) | 0.956 |
| Stilbenes | Prevalent cases/n | 237/622 | 237/617 | 273/637 |
| Model 1. OR (95%CI) | Ref. | 0.90 (0.70, 1.15) | 1.01 (0.80, 1.28) | 0.652 |
| Model 2. OR (95%CI) | Ref. | 0.84 (0.64, 1.09) | 0.75 (0.55, 1.03) | 0.131 |
| Model 3. OR (95%CI) | Ref. | 0.86 (0.66, 1.13) | 0.78 (0.57, 1.07) | 0.180 |
| Model 4. OR (95%CI) | Ref. | 0.87 (0.66, 1.13) | 0.79 (0.57, 1.10) | 0.236 |
| Lignans | Prevalent cases/n | 249/632 | 252/611 | 246/633 |
| Model 1. OR (95%CI) | Ref. | 0.98 (0.78, 1.24) | 0.92 (0.72, 1.16) | 0.449 |
| Model 2. OR (95%CI) | Ref. | 0.97 (0.77, 1.24) | 1.92 (0.73, 1.18) | 0.522 |
| Model 3. OR (95%CI) | Ref. | 0.98 (0.77, 1.25) | 0.91 (0.71, 1.16) | 0.448 |
| Tyrosols | Prevalent cases/n | 241/610 | 245/625 | 261/641 |
| Model 1. OR (95%CI) | Ref. | 0.88 (0.69, 1.12) | 0.85 (0.67, 1.08) | 0.220 |
| Model 2. OR (95%CI) | Ref. | 0.86 (0.67, 1.10) | 0.80 (0.62, 1.03) | 0.111 |
| Model 3. OR (95%CI) | Ref. | 0.86 (0.67, 1.11) | 0.82 (0.64, 1.06) | 0.156 |
| Alkylphenols | Prevalent cases/n | 260/648 | 245/626 | 242/626 |
| Model 1. OR (95%CI) | Ref. | 1.02 (0.80, 1.31) | 1.14 (0.90, 1.45) | 0.241 |
| Model 2. OR (95%CI) | Ref. | 1.07 (0.84, 1.38) | 1.31 (1.01, 1.70) | 0.040 |
| Model 3. OR (95%CI) | Ref. | 1.08 (0.84, 1.39) | 1.34 (1.03, 1.74) | 0.027 |

Model 1: Logistic regression model adjusted for age and total energy intake. Model 2: As in Model 1 and additionally adjusted for marital status, education, smoking, physical activity, sleep duration during weekdays and during the weekend, alcohol consumption, total fiber intake, body mass index, and diabetes. Model 3: As in Model 2 and additionally adjusted for LDL and HDL cholesterol and systolic and diastolic blood pressure. Model 4: As in Model 3 and flavonoids and stilbenes were mutually adjusted.

CACS Coronary Calcium Agatston Score, CI confidence interval, OR odds ratio.
dilatation, early plaque development, and growth) to vessel occlusion (thrombosis) [34]. Although it is known that ethanol favorably modifies the lipid pattern by decreasing total plasma cholesterol, in particular LDL, and by increasing HDL cholesterol, cardiovascular risk reduction attributed to wine is suggested to be linked largely to the effect of non-alcoholic components, mainly resveratrol, on the vascular wall and blood cells [35, 36].

In this study population, predominant source of both flavonoids and stilbenes was red wine and, formerly we also had demonstrated that moderate alcohol consumption was associated with lower prevalence of femoral artery subclinical atherosclerosis in this same cohort. Atherosclerosis was lower in ever-smokers who consumed between 2 g/d and 30 g/d with respect to those ever-smokers who were abstainers (OR 0.70; 95% CI 0.49–0.99; P < 0.05) [37]. Our results are adjusted for alcohol, and therefore, the effect of flavonoids and stilbenes is independent of the ethanol present in the wine.

Stilbenes are non-flavonoid polyphenols, characterized by the presence of a 1,2-diphenylethylene nucleus in their structure, and resveratrol and its derivatives are its main representatives [38]. Stilbenes are present mainly in red grapes, red wine, some kinds of tea, berries and peanuts, though their levels are very low in foods overall [39]. Notoriously, in this sample, while flavonoids represented close to 42% of the total dietary polyphenols intake, stilbenes represented less than 0.5%. However, it is known that the polyphenols that are the most common in the human diet are not necessarily the most active within the body, either because they have a lower intrinsic activity or because they are poorly absorbed from the intestine, highly metabolized, or rapidly eliminated [1]. Thus, stilbenes are among the most biologically active polyphenols contained in wine and, among them, resveratrol (trans-3,4′,5-trihydroxystilbene) has shown several benefits on the vascular system including anti-atherogenic, anti-inflammatory and anti-oxidative effects [40, 41]. Resveratrol has been found in urine samples of subjects who have drunk a glass of wine per week or three glasses per week after 3 or 5 days after last consumption, respectively [42]. Because resveratrol is mainly present in grape berry skins but not in flesh, and a major factor influencing its production is the fermentation time, white wine (which traditionally undergoes a shorter maceration time) contains only low amounts of resveratrol as compared with red wine [43]. While fruits were the major source of flavonoids in the Spanish population [39], the specific sources of variability in flavonoids intake in this study population were cacao, wine, and cherries/plums. This coincided with another study in the Spanish population [2].

Several plausible underlying biological mechanisms have been postulated to explain the beneficial effects of the polyphenols contained in red wine on the progression of atherosclerosis [40, 44]. Beneficial effects of resveratrol on vascular function go beyond its potential to inhibit the generation of oxidative stress/reactive oxygen species. Further effects of resveratrol in favor of the prevention of atherosclerosis include regulation of vasodilator and vasoconstrictor production, anti-inflammation, inhibition of modification of low-density lipoproteins, anti-platelet aggregation [40, 41, 45]. Resveratrol suppresses inflammation by inhibiting cyclooxygenase-1 and-2; lipooxygenases, epoxygenases and synthesis of prostaglandins and eicosanoids, and altering the nitric oxide generation [46]. Flavonoids also share many of these anti-atherogenic effects [47, 48].

Several limitations of our study must be recognized. First, differences between individuals in the absorption and metabolism of these plant bioactive compounds and the heterogeneity in their biological response [49] have not been taken into account. Likewise, although the FFQ provides an adequate assessment of an individual’s usual diet [17] and some validation studies have shown that FFQs are reasonable tools for estimating polyphenols intake [50], because of its self-reported nature and the potential recall bias, potential inaccuracies in the dietary assessment may exist. Also, the estimation of polyphenol intake was performed using Phenol-Explore database with the exception of three specific foods (leek, thistle, and honey), for which it had to be used the United States Department of Agriculture (USDA) database (https://www.ars.usda.gov/nutrientdata). Consequently, we cannot rule out the existence of a certain level of information misclassification (although it would be a non-differential misclassification since the error would be unrelated to the presence of the outcome). Because polyphenol intake measurement using dietary questionnaires is challenging, biomarkers for polyphenol exposure would be very useful for validating these findings in future research.

Second, the cross-sectional design of our study prevents us from establishing a causal link between polyphenols intake and subclinical atherosclerosis. However, since the atherosclerosis is subclinical, reverse causation is highly unlikely. Third, the limited external validity of our findings should also be mentioned, as the cohort was not representative of the general population. However, there is no biological evidence by which these results found in male workers might not be extended to the general population. And finally, despite adjusting for a wide range of potential confounders, we cannot rule out residual confounding.

This study notably presents important strengths, such as its novelty, the quality of the methodology used to collect clinical data and to quantify plaques in different territories and coronary calcium. These measurements capture information about the atherosclerosis distribution and have strong published support of their value for clinical risk prediction. Also, the detailed data collection for confounders, including
accurate measurements of blood pressure and serum lipids, helps reduce confounding.

As a conclusion, in this study of middle-age Spanish working men, we found that those consuming the highest amount of dietary flavonoids and stilbenes have lower prevalence of subclinical atheroma plaques and coronary calcium. Thus, the consumption of foods high in these compounds could prevent cardiovascular risk from very early stages.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00394-022-02823-0.

Author contributions CD-V conceived the presented idea, performed the computations and was the major contributor in writing the manuscript. RDM and HMS derived the polyphenols in the database, assist in writing the manuscript. PG-C and ML verified the analytical methods and supervised the findings of this work. All authors read, reviewed, and approved the final manuscript.

Funding Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study was also supported in part by CIBERCV, CIBERESP and Grants: PIE16/00022, P117/1709, P119/00948, P210/144 from the Instituto de Salud Carlos III (co-supported by the European Regional Development Fund ‘Investing in your future’). CD-V has a Talent Attraction Contract (‘Contrato Atracción de Talento’) from the Regional Government of the Madrid Community/IMDEA Food.

Availability of data and materials The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Competing interests The authors declare that they have no competing interests.

Ethics approval and consent to participate The study was approved by Clinical Research Ethics Committee of Aragon (CEICA).

Consent to publish All participants gave informed consent prior to inclusion in the study. This investigation conformed to all principles outlined in the Declaration of Helsinki.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Manach C, Scalbert A, Morand C, Réméry C, Jiménez L (2004) Polyphenols: food sources and bioavailability. Am J Clin Nutr 79(5):727–747. https://doi.org/10.1093/ajcn/79.5.7277
2. Mendonca RD, Carvalho NC, Martin-Moreno JM, Pimenta AM, Lopes ACS, Gea A, Martínez-González MA, Bres-Rastrollo M (2019) Total polyphenol intake, polyphenol subtypes and incidence of cardiovascular disease: The SUN cohort study. Nutr Metab Cardiovasc Dis 29(1):69–78. https://doi.org/10.1016/j.numecd.2018.09.012
3. Raman G, Avendano EE, Chen S, Wang J, Matson J, Gayer B, Novotny JA, Cassidy A (2019) Dietary intakes of flavan-3-ols and cardiometabolic health: systematic review and meta-analysis of randomized trials and prospective cohort studies. Am J Clin Nutr 110(5):1067–1078. https://doi.org/10.1093/ajcn/nqz178
4. Rienks J, Barbaresko J, Nohlings U (2017) Association of polyphenol biomarkers with cardiovascular disease and mortality risk: a systematic review and meta-analysis of observational studies. Nutrients. https://doi.org/10.3390/nu9040415
5. Tresserra-Rimbau A, Rimm EB, Medina-Remón A, Martínez-González MA, de la Torre R, Corella D, Salas-Salvador J, Gomez-Gracia E, Lapetra J, Aros F, Fiol M, Ros E, Serra-Majem L, Pinto X, Saez GT, Basora J, Sori JLV, Martinez JA, Vinyoles E, Ruiz-Gutierrez V, Estruch R, Lamuela-Raventos RM, Investigators PS (2014) Inverse association between habitual polyphenol intake and incidence of cardiovascular events in the PREDIMED study. Nutr Metab Cardiovasc Dis 24(6):639–647. https://doi.org/10.1016/j.numecd.2013.12.014
6. Andriantsitohaina R, Auger C, Chataigneau T, Etienne-Sellom N, Li H, Martinez MC, Schini-Kerth VB, Laher I (2012) Molecular mechanisms of the cardiovascular protective effects of polyphenols. Br J Nutr 108(9):1532–1549. https://doi.org/10.1017/S0007114512003406
7. Garcia-Lafuente A, Guillen E, Villares A, Rostagno MA, Martinez JA (2009) Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm Res 58(9):537–552. https://doi.org/10.1007/s00011-009-0037-3
8. Steffen Y, Gruber C, Schewe T, Sies H (2008) Mono-O-methylated flavanols and other flavonoids as inhibitors of endothelial NADPH oxidase. Arch Biochem Biophys 469(2):209–219. https://doi.org/10.1016/j.abb.2007.10.012
9. Medina-Remon A, Casas R, Tresserra-Rimbau A, Ros E, Martinez-González MA, Fito M, Corella D, Salas-Salvador J, Lamuela-Raventos RM, Estruch R, Investigators PS (2017) Polyphenol intake from a Mediterranean diet decreases inflammatory biomarkers related to atherosclerosis: a substudy of the PREDIMED trial. Br J Clin Pharmacol 83(1):114–128. https://doi.org/10.1111/bcp.12986
10. Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362(6423):801–809. https://doi.org/10.1038/362801a0
11. Budoff MJ, Nasir K, McClelland RL, Detrano R, Wong N, Blumenthal RS, Kondos G, Kronmal RA (2009) Coronary calcium predicts events better with absolute calcium scores than age-sex-race/ethnicity percentiles: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 53(4):345–352. https://doi.org/10.1016/j.jacc.2008.07.072
12. Lo-Kioeng-Shioe MS, Rijlaarsdam-Hermens D, van Domburg RT, Hadamitzky M, Lima JAC, Hoeks SE, Deckers JW (2020) Prognostic value of coronary artery calcium score in symptomatic
individuals: a meta-analysis of 34,000 subjects. Int J Cardiol 299:56–62. https://doi.org/10.1016/j.ijcard.2019.06.003

13. Tota-Maharaj R, Blaha MJ, Blankstein R, Silverman MG, Eng J, Shaw LJ, Blumenthal RS, Budoff MJ, Nasir K (2014) Association of coronary artery calcium and coronary heart disease events in young and elderly participants in the multi-ethnic study of atherosclerosis: a secondary analysis of a prospective, population-based cohort. Mayo Clin Proc 89(10):1350–1359. https://doi.org/10.1016/j.mayocp.2014.05.017

14. Laclaustra M, Casasnovas JA, Fernandez-Ortiz A, Fuster V, Leon-Latre M, Jimenez-Borreguero LJ, Pocovi M, Hordata-Roca Y, Ordovas JM, Jarauta E, Guallar E, Ibanez B, Civeira F (2016) Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium: the AWHS Study. J Am Coll Cardiol 67(11):1263–1274. https://doi.org/10.1016/j.jacc.2015.12.056

15. Casasnovas JA, Alcaide V, Civeira F, Guallar E, Ibanez B, Borreguero JJ, Laclaustra M, Leon M, Penalvo JL, Ordovas JM, Pocovi M, Sanz G, Fuster V (2012) Aragon workers’ health study design and cohort description. BMC Cardiovasc Disord 12:45. https://doi.org/10.1186/1471-2261-12-45

16. de la Fuente-Arrillaga C, Ruiz ZV, Bes-Rastrollo M, Sampson L, Martinez-Gonzalez MA (2010) Reproducibility of an FFQ validated in Spain. Public Health Nutr 13(9):1364–1372. https://doi.org/10.1017/S136898009993065

17. Fernández-Ballart JD, Piñol JL, Zazpe I, Corella D, Carrasco P, Toro J, Perez-Bauer M, Martinez-Gonzalez MA, Salas-Salvadó J, Martin-Loeches IM, Guallar E, Martín-Moreno JM (2010) Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. Br J Nutr 103(12):1808–1816

18. Martin-Moreno JM, Boyle P, Gorgojo L, Maisonneuve P, Fernandez-Rodriguez JC, Salvin J, Willett WC (1993) Development and validation of a food frequency questionnaire in Spain. Int J Epidemiol 22(3):512–519. https://doi.org/10.1093/ije/23.3.512

19. Rothwell JA, Medina-Remon A, Perez-Jimenez J, Neveu V, Knaze V, Simiani M, Scalbert A (2015) Effects of food processing on polyphenol contents: a systematic analysis using Phenol-Explorer data. Mol Nutr Food Res 59(1):160–170. https://doi.org/10.1002/mnr.201400494

20. Gunathilake H, Ranaweera K, Rupasinghe HPV (2018) Influence of boiling, steaming and frying of selected leafy vegetables on the in vitro anti-inflammatory associated biological activities. Plants. https://doi.org/10.3390/plants7010022

21. Willett W, Stampfer MJ (1986) Total energy intake: implications for epidemiologic analyses. Am J Epidemiol 124(1):17–27. https://doi.org/10.1093/aje/124.1.17

22. Muntendam P, McCall C, Sanz G, Fuster V, High-Risk Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium: the AWHS Study. J Am Coll Cardiol 67(11):1263–1274. https://doi.org/10.1016/j.jacc.2015.12.056

23. Junyent M, Gilabert R, Zambon D, Pocovi M, Mallen M, Cofan M, Nunez I, Civeira F, Tejedor D, Ros E (2008) Femoral atherosclerosis in heterozygous familial hypercholesterolemia: influence of the genetic defect. Arterioscler Thromb Vasc Biol 28(3):580–586. https://doi.org/10.1161/ATVBAHA.107.153841

24. Inaba Y, Chen JA, Bergmann SR (2012) Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. Atherosclerosis 220(1):128–133. https://doi.org/10.1016/j.atherosclerosis.2011.06.044

25. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15(4):827–832. https://doi.org/10.1016/0735-1097(90)90282-t

26. Erbel R, Mohlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A, Dragano N, Gronemeyer D, Siebel R, Kalsch H, Brocker-Preuss M, Mann K, Siegist J, Jockel KH, Heinz Nixdorf Recall Study Investigative (2010) Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall Study. J Am Coll Cardiol 56(17):1397–1406. https://doi.org/10.1016/j.jacc.2010.06.030

27. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502

28. Martinez-Gonzalez MA, Lopez-Fontana C, Varo JJ, Sanchez-Villegas A, Martinez JA (2005) Validation of the Spanish version of the physical activity questionnaire used in the Nurses’ Health Study and the Health Professionals’ Follow-up Study. Public Health Nutr 8(7):920–927. https://doi.org/10.1079/phn2005745

29. Ahmed HM, Blaha MJ, Nasir K, Jones SR, Riveria JJ, Agatston A, Blankstein R, Wong ND, Lakoski S, Budoff MJ, Burke GL, Sibley CT, Ouyang P, Blumenthal RS (2013) Low-risk lifestyle, coronary calcium, cardiovascular events, and mortality: results from MESA. Am J Epidemiol 178(1):12–21. https://doi.org/10.1093/aje/kws453

30. White IR, Royston P, Wood AM (2011) Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 30(4):377–399. https://doi.org/10.1002/sim.4067

31. Lee KJ, Carlin JB (2010) Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation. Am J Epidemiol 171(5):624–632. https://doi.org/10.1093/aje/kwp425

32. Wang X, Ouyang YY, Liu J, Zhao G (2014) Flavonoid intake and risk of CVD: a systematic review and meta-analysis of prospective cohort studies. Br J Nutr 111(1):1–11. https://doi.org/10.1017/S000711451300278X

33. Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB, De Gaetano G (2002) Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 105(24):2836–2844. https://doi.org/10.1171/j.10.01.01.cir.0000018653.19969.01

34. Lippi G, Franchini M, Favaloro EJ, Targher G (2010) Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox.” Semin Thromb Hemost 36(1):59–70. https://doi.org/10.1055/s-0030-1248725

35. Castaldo L, Narvaez A, Izzo L, Graziani G, Gaspari A, Minno GD, Ritiene A (2019) Red wine consumption and cardiovascular health. Molecules. https://doi.org/10.3390/molecules24193626

36. Domínguez-López I, Parilli-Mosser I, Arancibia-Riveros C, Tresserra-Rimbau A, Martínez-González MA, Ortega-Azorín C, Salas-Salvadó J, Castañer O, Lapetra J, Arós F, Fiol M, Serramajer L, Pintó X, Gómez-Gracia E, Ros E, Lamuela-Raventós RM, Estruch R (2021) Urinary tartaric acid, a biomarker of wine intake, correlates with lower total and LDL cholesterol. Nutrients. https://doi.org/10.3390/nu13082883

37. Moreno-Francisco B, Pérez-Esteban A, Civeira F, Guallar-Castillón P, Casasnovas JA, Mateo-Gallego R, Jarauta E, Malo S, Laclaustra M (2020) Association between alcohol consumption and subclinical femoral atherosclerosis in smoking and non-smoking men: the AHWS study. Addiction 115(9):1754–1761. https://doi.org/10.1111/adb.15012

38. Shen T, Wang XN, Lou HX (2009) Natural stilbenes: an overview. Nat Prod Rep 26(7):916–935. https://doi.org/10.1039/b905966a

39. Zamora-Ros R, Andres-Lacueva C, Lamuela-Raventos RM, Benenguer T, Jakssyn P, Martinez C, Sanchez MJ, Navarro C, Chirlaque MD, Tormo MJ, Quiros JR, Amiano P, Dorronso M, Lagranaga N, Barricarte A, Ardanaz E, Gonzalez CA (2008) Concentrations of resveratrol and derivatives in foods and estimation of dietary intake in a Spanish population: European Prospective
40. Fan E, Zhang L, Jiang S, Bai Y (2008) Beneficial effects of resveratrol on atherosclerosis. J Med Food 11(4):610–614. https://doi.org/10.1089/jmf.2007.0091
41. Ramprasath VR, Jones PJ (2010) Anti-atherogenic effects of resveratrol. Eur J Clin Nutr 64(7):660–668. https://doi.org/10.1038/ejcn.2010.77
42. Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventos RM, Estruch R, Vazquez-Agell M, Serrano-Martinez M, Jaeger W, Andres-Lacueva C (2006) Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem 52(7):1373–1380. https://doi.org/10.1373/clinchem.2005.065870
43. Fremont L (2000) Biological effects of resveratrol. Life Sci 66(8):663–673. https://doi.org/10.1016/s0024-3205(99)00410-5
44. Djousse L, Lee IM, Buring JE, Gaziano JM (2009) Alcohol consumption and risk of cardiovascular disease and death in women: potential mediating mechanisms. Circulation 120(3):237–244. https://doi.org/10.1161/CIRCULATIONAHA.108.832360
45. Wu JM, Wang ZR, Hsieh TC, Bruder JL, Zou JG, Huang YZ (2001) Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine (Review). Int J Mol Med 8(1):3–17. https://doi.org/10.3892/ijmm.8.1.3
46. Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ (2008) Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev 66(8):445–454. https://doi.org/10.1111/j.1753-4887.2008.00076.x
47. Fardoun MM, Maaliki D, Halabi N, Iratni R, Bitto A, Baydoun E, Eid AH (2020) Flavonoids in adipose tissue inflammation and atherosclerosis: one arrow, two targets. Clin Sci 134(12):1403–1432. https://doi.org/10.1042/CS20200356
48. Sanchez M, Romero M, Gomez-Guzman M, Tamargo J, Perez-Vizcaino F, Duarte J (2019) Cardiovascular effects of flavonoids. Curr Med Chem 26(39):6991–7034. https://doi.org/10.2174/0929867326666181220094721
49. Manach C, Milenkovic D, Van de Wiele T, Rodriguez-Mateos A, de Roos B, García-Conesa MT, Landberg R, Gibney ER, Heinonen M, Tomas-Barberan F, Morand C (2017) Addressing the inter-individual variation in response to consumption of plant food bioactives: towards a better understanding of their role in healthy aging and cardiometabolic risk reduction. Mol Nutr Food Res. https://doi.org/10.1002/mnfr.201600557
50. Burkholder-Cooley NM, Rajaram SS, Haddad EH, Oda K, Fraser GE, Jaceldo-Sieg K (2017) Validating polyphenol intake estimates from a food-frequency questionnaire by using repeated 24-h dietary recalls and a unique method-of-triads approach with 2 biomarkers. Am J Clin Nutr 105(3):685–694. https://doi.org/10.3945/ajcn.116.137174